<?xml version="1.0" encoding="ISO-8859-1"?>
<rss version="2.0">
<channel>
<title>PRWeb.com Press Release Feed - PRWeb Press Release Account Feed</title>
<link>http://www.rsspad.com/rss2a/33091.xml</link>
<description>PRWeb.com Press Release Feed - Press Releases</description>
<language>en</language>
<managingEditor>xml@emediawire.com</managingEditor>
<webMaster>xml@emediawire.com</webMaster>
<ttl>30</ttl>
<item>
     <title>Kibow Biotech Inc Announces a Licensing Agreement of its &#8220;Enteric Dialysis&#8482;&#8221; Technology and &#8220;Kibow Biotics&#174;&#8221; Product Formulation to Vetoquinol USA Inc</title>
     <link>http://www.prweb.com/releases/2006/05/prweb391172.htm</link><description>   <![CDATA[ <P>Kibow Biotics&#174; (AZODYL&#8482;) targets uremic toxins, reduces Azotemia in dogs and cats with Chronic Kidney Disease.  Hence, this product is also expected to improve the quality of live and longetivity in pets.  Similar applications in human kidney failure applications is being clinically tested by Kibow Biotech Inc. (PRWeb May 28, 2006)</P>
                                <P>Read the full story at <a href="http://www.prweb.com/releases/2006/05/prweb391172.htm">http://www.prweb.com/releases/2006/05/prweb391172.htm</a></P>]]>
                </description><pubDate>Sun, 28 May 2006 07:00:00 GMT</pubDate>
        <guid isPermaLink="true">http://www.prweb.com/releases/2006/05/prweb391172.htm</guid>
        </item>
</channel>
</rss>